Despite a lack of clinical trial data, β-blockers are widely prescribed to dialysis patients. There is considerable heterogeneity among β-blocker medications in terms of key pharmacologic variables such as cardioselectivity and dialyzability. While the majority of existing evidence indicates a survival benefit with β-blocker use in dialysis patients, the optimal β-blocker agent for this population remains uncertain.
No takes yet. Share an insight, caveat, or question.
Hundemer et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: